Comparing incomplete atypical femur fractures in patients with or without bisphosphonate treatment: radiography and bone morphology in a retrospective study of 19 cases
DOI:
https://doi.org/10.2340/17453674.2025.43899Keywords:
Atypical Femur Fractures, Bone, Cells, Fractures, Hip, OsteoporosisAbstract
Background and purpose: Atypical femur fractures (AFF) are associated with bisphosphonate (BP) treatment, although 10–50% of AFF patients have never used BPs. We aimed to compare the medical history, radiographs, and bone biopsies from the fracture site of patients with AFF with (BP group) and without BP exposure (non-BP group).
Methods: Between 2008 and 2021, we included 19 patients aged ≥ 50 years with incomplete AFF. During prophylactic nailing for thigh pain, a biopsy was taken that included the visible fracture line. Medical charts and radiographs were reviewed, and biopsies were analyzed histologically.
Results: In the non-BP group (n = 9; mean age 70 years) patients had diseases affecting bone tissue properties (n = 3), pathological structural variations of the femur geometry or a fatigue-type mechanism (n = 3), or no identified causative patho-mechanism (n = 3). In the BP group (n = 10; mean age, 77 years) 2 patients had pathological variations of femur geometry and all used BPs. In the non-BP group, the fracture line was surrounded by bone resorption (n = 6) and cortical irregularities (n = 3), while the fracture line was restricted to a well-defined line in all patients in the BP group. The bone volume fraction (BV/TV) was on average 18% lower (95% confidence interval –35 to –1.2) in the non-BP group.
Conclusion: AFF in the non-BP group are associated with bone metabolic diseases or deviations in whole-bone geometry and have a specific radiographic appearance at the fracture site whereas antiresorptive treatment appears to be the predominant etiological factor in the BP group.
Downloads
References
Ural A. Biomechanical mechanisms of atypical femoral fracture. J Mech Behav Biomed Mater 2021; 124: 104803. doi: 10.1016/j.jmbbm.2021.104803. DOI: https://doi.org/10.1016/j.jmbbm.2021.104803
Zhou W, van Rooij J G, van de Laarschot D M, Zervou Z, Bruggenwirth H, Appelman-Dijkstra N M, et al. Prevalence of monogenic bone disorders in a Dutch cohort of atypical femur fracture patients. J Bone Miner Res 2023. doi: 10.1002/jbmr.4801. DOI: https://doi.org/10.1002/jbmr.4801
Charoenngam N, Thongpiya J, Yingchoncharoen P, Ponvilawan B, Marangoz M S, Chenbhanich J, et al. Atypical femoral fracture in hypophosphatasia: a systematic review. Int J Endocrinol 2023; 2023: 5544148. doi: 10.1155/2023/5544148. DOI: https://doi.org/10.1155/2023/5544148
Gani L U, Anthony N F, Dacay L M, Tan P T, Chong L R, King T F J. Characteristics of bisphosphonate and non-bisphosphonate related atypical femoral fracture in a South East Asian population: secondary analysis. Bone 2022; 162: 116455. doi: 10.1016/j.bone.2022.116455. DOI: https://doi.org/10.1016/j.bone.2022.116455
Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011; 364(18): 1728-37. doi: 10.1056/NEJMoa1010650. DOI: https://doi.org/10.1056/NEJMoa1010650
Bennell K L, Malcolm S A, Wark J D, Brukner P D. Models for the pathogenesis of stress fractures in athletes. Br J Sports Med 1996; 30(3): 200-4. doi: 10.1136/bjsm.30.3.200. DOI: https://doi.org/10.1136/bjsm.30.3.200
Pentecost R L, Murray R A, Brindley H H. Fatigue, insufficiency, and pathologic frac-tures. JAMA 1964; 187(13): 1001-4. doi: 10.1001/jama.1964.03060260029006. DOI: https://doi.org/10.1001/jama.1964.03060260029006
Oh Y, Yamamoto K, Hashimoto J, Fujita K, Yoshii T, Fukushima K, et al. Biological activity is not suppressed in mid-shaft stress fracture of the bowed femoral shaft unlike in “typical” atypical subtrochanteric femoral fracture: a proposed theory of atypical femoral fracture subtypes. Bone 2020; 137: 115453. doi: 10.1016/j.bone.2020.115453. DOI: https://doi.org/10.1016/j.bone.2020.115453
Black D M, Geiger E J, Eastell R, Vittinghoff E, Li B H, Ryan D S, et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med 2020; 383(8): 743-53. doi: 10.1056/NEJMoa1916525. DOI: https://doi.org/10.1056/NEJMoa1916525
Odvina C V, Zerwekh J E, Rao D S, Maalouf N, Gottschalk F A, Pak C Y. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90(3): 1294-301. doi: 10.1210/jc.2004-0952. DOI: https://doi.org/10.1210/jc.2004-0952
Loi F, Cordova L A, Pajarinen J, Lin T H, Yao Z, Goodman S B. Inflammation, frac-ture and bone repair. Bone 2016; 86: 119-30. doi: 10.1016/j.bone.2016.02.020. DOI: https://doi.org/10.1016/j.bone.2016.02.020
Shane E, Burr D, Abrahamsen B, Adler R A, Brown T D, Cheung A M, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014; 29(1): 1-23. doi: 10.1002/jbmr.1998. DOI: https://doi.org/10.1002/jbmr.1998
Koh J S, Goh S K, Png M A, Kwek E B, Howe T S. Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture? J Orthop Trauma 2010; 24(2): 75-81. doi: 10.1097/BOT.0b013e3181b6499b. DOI: https://doi.org/10.1097/BOT.0b013e3181b6499b
Mahjoub Z, Jean S, Leclerc J T, Brown J P, Boulet D, Pelet S, et al. Incidence and char-acteristics of atypical femoral fractures: clinical and geometrical data. J Bone Miner Res 2016; 31(4): 767-76. doi: 10.1002/jbmr.2748. DOI: https://doi.org/10.1002/jbmr.2748
Yoo H, Cho Y, Park Y, Ha S. Lateral femoral bowing and the location of atypical femo-ral fractures. Hip Pelvis 2017; 29(2): 127-32. doi: 10.5371/hp.2017.29.2.127. DOI: https://doi.org/10.5371/hp.2017.29.2.127
Lee K J, Kim B S, Kim K T, Jung G H. Three-dimensional morphologic features of Asian atypical femur and clinical implications of cephalomedullary nail fixation: computational measurement at actual size. Injury 2022; 53(12): 4090-8. doi: 10.1016/j.injury.2022.09.044. DOI: https://doi.org/10.1016/j.injury.2022.09.044
Schilcher J, Sandberg O, Isaksson H, Aspenberg P. Histology of 8 atypical femoral fractures: remodeling but no healing. Acta Orthop 2014; 85(3): 280-6. doi: 10.3109/17453674.2014.916488. DOI: https://doi.org/10.3109/17453674.2014.916488
Massy Z, Drueke T. Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease. J Nephrol 2017; 30(5): 629-34. doi: 10.1007/s40620-017-0397-7. DOI: https://doi.org/10.1007/s40620-017-0397-7
Weinstein R S, Roberson P K, Manolagas S C. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 2009; 360(1): 53-62. doi: 10.1056/NEJMoa0802633. DOI: https://doi.org/10.1056/NEJMoa0802633
Schilcher J, Koeppen V, Aspenberg P, Michaelsson K. Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop 2015; 86(1): 100-7. doi: 10.3109/17453674.2015.1004149. DOI: https://doi.org/10.3109/17453674.2015.1004149
Schilcher J, Bernhardsson M, Aspenberg P. Chronic anterior tibial stress fractures in athletes: no crack but intense remodeling. Scand J Med Sci Sports 2019; 29(10): 1521-8. doi: 10.1111/sms.13466. DOI: https://doi.org/10.1111/sms.13466
Hughes J M, Popp K L, Yanovich R, Bouxsein M L, Matheny R W Jr. The role of adaptive bone formation in the etiology of stress fracture. Exp Biol Med (Maywood) 2017; 242(9): 897-906. doi: 10.1177/1535370216661646. DOI: https://doi.org/10.1177/1535370216661646
Starr J, Tay Y K D, Shane E. Current understanding of epidemiology, pathophysiology, and management of atypical femur fractures. Curr Osteoporos Rep 2018; 16(4): 519-29. doi: 10.1007/s11914-018-0464-6. DOI: https://doi.org/10.1007/s11914-018-0464-6
Png M A, Mohan P C, Koh J S B, Howe C Y, Howe T S. Natural history of incom-plete atypical femoral fractures in patients after a prolonged and variable course of bisphospho-nate therapy: a long-term radiological follow-up. Osteoporos Int 2019; 30(12): 2417-28. doi: 10.1007/s00198-019-05067-7. DOI: https://doi.org/10.1007/s00198-019-05067-7
Aki T, Hashimoto K, Uozumi H, Saito M, Sugawara K, Suzuki M, et al. Morphological and morphometrical analyses of fracture-healing sites of an atypical femoral fracture in patients with and without long-term bisphosphonate treatment for osteoporosis: a report of two cases. Tohoku J Exp Med 2021; 253(4): 261-7. doi: 10.1620/tjem.253.261. DOI: https://doi.org/10.1620/tjem.253.261
Somford M P, van Ruijven L J, Kloen P, Bakker A D. Histological and micro computed tomography analysis of a femoral stress fracture associated with prolonged bisphosphonate use. Clin Cases Miner Bone Metab 2017; 14(1): 92-6. doi: 10.11138/ccmbm/2017.14.1.092. DOI: https://doi.org/10.11138/ccmbm/2017.14.1.092
Nguyen H H, van de Laarschot D M, Verkerk A, Milat F, Zillikens M C, Ebeling P R. Genetic risk factors for atypical femoral fractures (AFFs): a systematic review. JBMR Plus 2018; 2(1): 1-11. doi: 10.1002/jbm4.10024. DOI: https://doi.org/10.1002/jbm4.10024
Franceschetti P, Bondanelli M, Caruso G, Ambrosio M R, Lorusso V, Zatelli M C, et al. Risk factors for development of atypical femoral fractures in patients on long-term oral bisphosphonate therapy. Bone 2013; 56(2): 426-31. doi: 10.1016/j.bone.2013.07.010. DOI: https://doi.org/10.1016/j.bone.2013.07.010
Clegg S M, Eiel E S, Fine S, Gafni R I, Most M J. Atypical fragility fractures due to bony or soft tissue phosphaturic mesenchymal tumors: a report of two cases. Case Rep Orthop 2023; 2023: 5614065. doi: 10.1155/2023/5614065. DOI: https://doi.org/10.1155/2023/5614065
Girgis C M, Sher D, Seibel M J. Atypical femoral fractures and bisphosphonate use. N Engl J Med 2010; 362(19): 1848-9. doi: 10.1056/NEJMc0910389. DOI: https://doi.org/10.1056/NEJMc0910389
Lee I, Son D-W, Park J H, Park J H. Drug-induced hyperprolactinemia results in atypi-cal atypical fracture. Hip Pelvis 2021; 33(2): 102-7. doi: 10.5371/hp.2021.33.2.102. DOI: https://doi.org/10.5371/hp.2021.33.2.102
Berger G K, Graf A R, Wooldridge A N, Hackbarth D A. Complex femoral reconstruc-tion following pathologic subtrochanteric femur fracture secondary to Paget’s disease of the bone: a case report with long-term follow-up. J Orthop Case Rep 2020; 10(3): 19-22. doi: 10.13107/jocr.2020.v10.i03.1730.
Popp K L, Caksa S, Martinez-Betancourt A, Yuan A, Tsai J, Yu E W, et al. Cortical bone material strength index and bone microarchitecture in postmenopausal women with atypi-cal femoral fractures. J Bone Miner Res 2019; 34(1): 75-82. doi: 10.1002/jbmr.3590. DOI: https://doi.org/10.1002/jbmr.3590
Farr J N, Drake M T, Amin S, Melton L J 3rd, McCready L K, Khosla S. In vivo as-sessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res 2014; 29(4): 787-95. doi: 10.1002/jbmr.2106. DOI: https://doi.org/10.1002/jbmr.2106
Lim S J, Yeo I, Yoon P W, Yoo J J, Rhyu K H, Han S B, et al. Incidence, risk factors, and fracture healing of atypical femoral fractures: a multicenter case-control study. Osteoporos Int 2018; 29(11): 2427-35. doi: 10.1007/s00198-018-4640-4. DOI: https://doi.org/10.1007/s00198-018-4640-4
Koh J H, Myong J P, Jung S M, Lee J, Kwok S K, Park S H, et al. Atypical femoral fracture in rheumatoid arthritis patients treated with bisphosphonates: a nested case-control study. Arthritis Rheumatol 2016; 68(1): 77-82. doi: 10.1002/art.39429. DOI: https://doi.org/10.1002/art.39429
Additional Files
Published
How to Cite
License
Copyright (c) 2025 Georg Zdolsek, Hans Peter Bögl, Rickard Sand, Aneta Liszka, Anna Fahlgren, Jörg Schilcher
This work is licensed under a Creative Commons Attribution 4.0 International License.
